GlassScriptPhysician profile
Toxi Edwards
NPI 1760152466
$3,480.33
in general payments reported to CMS, 2019-2025
20 companies · $649 in 2025
The $649 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $419 · 2023: $1,138 · 2024: $1,275 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,060.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $547.84 | 2024-2025 | |
| Glaxosmithkline, LLC. | $347.69 | 2023-2024 | Shingrix |
| Viiv Healthcare Company | $331.25 | 2025 | Cabenuva, Apretude |
| Emd Serono, INC. | $307.82 | 2023-2024 | Serostim |
| Genzyme Corporation | $233.10 | 2023-2024 | |
| Optinose US, INC. | $207.54 | 2023-2024 | |
| Abbvie INC. | $165.16 | 2022-2023 | |
| Theratechnologies INC. | $146.29 | 2023-2025 | Egrifta, Egrifta Sv |
| Kyowa Kirin, INC. | $139.51 | 2023 | |
| Sk Life Science, INC. | $124.10 | 2024 | Xcopri |
| Teva Pharmaceuticals USA, INC. | $110.94 | 2022 | |
| Sumitomo Pharma America, INC. | $104.69 | 2023 | Gemtesa |
| Exeltis, USA INC. | $103.35 | 2025 | Twirla, Slynd |
| Amgen INC. | $99.02 | 2023 | Repatha |
| Kowa Pharmaceuticals America, INC. | $94.69 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.57 | 2023 | Xifaxan |
| Braeburn INC. | $91.16 | 2024 | Brixadi |
| Sanofi-Aventis U.S. LLC | $81.88 | 2024 | |
| Edwards Lifesciences Corporation | $81.30 | 2022 | |
| Medtronic, INC. | $71.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toxi Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.